Speaker Profile

M.D., Pharm.D, Associate Commissioner For Women's Health - Office Of Women's Health, FDA

Dr. Kaveeta Vasisht is the Associate Commissioner for Women’s Health at the U.S. Food and Drug Administration (FDA). She is responsible for directing the Office of Women's Health at the FDA. Under her leadership, the Office works to advance the health of women through scientific programs, policy development, research, education and outreach. Prior to joining the Office of Women’s Health, Dr. Vasisht served as the Deputy Director for the Division of Clinical Trial Quality in the Office of Medical Policy in the Center for Drug Evaluation and Research. She has led multi-stakeholder international collaborations and policy development that are critical to the Agency’s approach to improving clinical trial quality and methodologies. She has worked to promote the inclusion of diverse populations in clinical trials. Dr. Vasisht began her career at the FDA in the Division of Metabolism and Endocrine Products, Office of New Drugs, where she served as the clinical expert on multidisciplinary teams in the review and evaluation of scientific data to make regulatory decisions regarding risk-benefit assessments on the safety and effectiveness of therapeutics to treat endocrine conditions for the U.S. population. Dr. Vasisht is board certified in both internal medicine and adult endocrinology and holds a Doctor of Pharmacy degree. She completed her internal medicine training as well as her fellowship training in adult endocrinology, diabetes and metabolism at the University of Chicago Hospitals, where she also served as a clinical instructor of medicine. She has completed a hospital pharmacy practice residency. Dr. Vasisht continues to practice endocrinology in a volunteer clinic. She obtained her medical degree from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School. Dr. Vasisht combines her clinical experience and academic training with her diverse regulatory background to further advance FDA’s mission to protect, promote and advance the health of women.

 Session Abstract – PMWC 2022 Silicon Valley

Track Co-Chairs:
Aleksandar Rajkovic, UCSF
Kathryn G. Schubert, Society for Women's Health Research

Researchers have long been recognizing the uniqueness of women’s health and its substantial effect on clinical practice, acknowledging the increasing appreciation of the importance of multidisciplinary approaches to health and disease. In every organ system, there are diseases that are unique to women, more common in women than in men, or characterized by differences in disease course in women compared to men. This Track will focus on the following topics related to Women’s Health:

  • Intro to Women's Health
    - Aleksandar Rajkovic, UCSF
  • US Regulatory/Personalized Medicine and Women's Health
    Session Chair: Kathryn G. Schubert, SWHR
    - Kaveeta Vasisht, FDA
  • Reproductive Health
    - Hakan Cakmak, UCSF
    - Laura Jelliffe-Pawlowski, UCSF
  • Pregnancy (PANEL)
    Session Chair: Yoel Sadovsky, UPMC
    - Virginia D. Winn, Stanford
    - Ananth Karumanchi, Cedars-Sinai Medical Center
    - Mira Moufarrej, Stanford University
  • Carrier Screening: Perspective on the new ACMG Practice Resource
    - James D Goldberg, Women's Health Medical Affairs
  • Biological Sex Differences in Disease + Inclusion of Women in Clinical Research/Innovation
    - Rhonda Voskuhl, UCLA
  • Cardiovascular Health
    - Nisha Parikh, UCSF
    - Michael Honigberg, Massachusetts General Hospital
    - Jennifer Ann Tremmel, Stanford
  • Bone Health/Osteoporosis & Menopause
    Session Chair: Risa Kagan, Sutter Health
    - Danit Ariel, Stanford
    - Massimiliano (Max) de Zambotti, SRI International
  • Showcase
    - Maneesh Jain, MirVie
    - Kevin P. Rosenblatt, NX Prenatal
    - Ripudaman Singh, ARCEDI Biotech
    - Michelle Perugini, Presagen
    - Claire Tomkins, Future Family